PURPOSE The Central Cancer Registry Center in Korea (KCCR) conducted a nationwide hospital-based cancer registry to provide basic statistical data on cancer. MATERIALS AND METHODS In 1999, 128 hospitals participated in the cancer registry program. All cancer registry data, which was submitted from the participating hospitals by diskettes during the year, were reviewed and analyzed by the committee members who were all Board-qualified clinical oncologists and pathologists. To avoid duplication, every resident registration number was compared by a computer. Case s that had been diagnosed by a histological examination were preferentially chosen for inclusion in this data. RESULTS Of 94,003 cases that were registered, there was a total of 8,452 (9.0%) duplication cases which were excluded.
Of the remaining 85,551 cases, there were 3,231 cases (3.8%) of carcinoma in situ (morphology code/2) which were excluded. A final total of 82,320 cases were analyzed. Of the analyzed cases, 46,908 (57.0%) were males and 35,412 (43.0%) were females. The leading age groups in the order of their relative frequency were those who were 60~64 years of age (15.3%), followed by the 55~59 age group (13.8%). The six leading primary cancer sites in the order of their relative frequency were stomach (20.7%), followed by the bronchus and lung (12.1%), the liver and intrahepatic bile duct (12.0%), the colorectum (9.9%), the breast (6.4%), and then the uterine cervix (5.0%). In males, the five leading primary cancer sites were the stomach (24.2%), the liver and intrahepatic bile duct (16.3%), the bronchus and lung (16.1%), the colorectum (9.7%), and the urinary bladder (3.3%). In females, the stomach (16.2%) was the most common cancer site, followed by the breast (14.7%), the uterine cervix (11.6%), the colorectum (10.2%), and the thyroid (6.8%). Among the 1,077 cases of childhood malignancies, leukemia (35.4%), CNS tumors (16.7%), malignant lymphomas (7.0%), and sympathetic nervous system tumors (6.9%) were the most common cancer types. CONCLUSION We analyzed and report the KCCR data from 128 nationwide hospitals during 1999.
Citations
Citations to this article as recorded by
Comparison of Dose Distribution between the Techniques of Non-small Cell Lung Cancer Seung-chul Lee, Young-jae Kim, Seongjoo Jang Journal of the Korean Society of Radiology.2016; 10(4): 233. CrossRef
Discussion on the usefulness of dose dynamic multi-leaf collimator-based plan to overcome dose limit of spinal cord in high-dose radiotherapy E.C. Kim, J.H. Cho, C.S. Park, D.H. Kim, C.W. Choi Radiation Effects and Defects in Solids.2014; 169(3): 265. CrossRef
Microsatellite Instability Is Associated with the Clinicopathologic Features of Gastric Cancer in Sporadic Gastric Cancer Patients Shin Hyuk Kim, Byung Kyu Ahn, Young Su Nam, Joo Youn Pyo, Young Ha Oh, Kang Hong Lee Journal of Gastric Cancer.2010; 10(4): 149. CrossRef
The Effect of Autophagy to Cell Death in Nutrient-Deprived H460 Cells Hye Yeon Jang, Hyang Jeong Jo, Ki Eun Hwhang, So Young Kim, Kang Kyoo Lee, Sun Rock Moon, Jeong Hyun Shin, Kyung Hwa Cho, Mi Kung Lee, Sam Youn Lee, Soon Ah Park, Jong Kun Park, Hui Jung Kim, Sei Hoon Yang Tuberculosis and Respiratory Diseases.2010; 69(2): 81. CrossRef
Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3 Tuong Vy Thi Le, Youngcheol Seo, Chun Jeih Ryu, Hye Ran Lee, Hyun-Ju Park Archives of Pharmacal Research.2010; 33(7): 1127. CrossRef
Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate Dong Won Ryu, Chang Wan Jun, Chung Han Lee Journal of Breast Cancer.2008; 11(2): 89. CrossRef
Relationship between meat and cereal consumption and colorectal cancer in Korea and Japan Sun‐Il Lee, Hong‐Young Moon, Jung‐Myun Kwak, Jin Kim, Byung‐Wook Min, Jun‐Won Um, Seon‐Han Kim Journal of Gastroenterology and Hepatology.2008; 23(1): 138. CrossRef
The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric Adenocarcinoma Young Soo Park, Min Young Jin, Yong Jin Kim, Jeong Hwan Yook, Byung Sik Kim, Se Jin Jang Annals of Surgical Oncology.2008; 15(7): 1968. CrossRef
Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma Jaehwi Song, Chang Jae Kim, Yong Gu Cho, Su Young Kim, Suk Woo Nam, Sug Hyung Lee, Nam Jin Yoo, Jung Young Lee, Won Sang Park Journal of Gastroenterology and Hepatology.2006; 21(8): 1286. CrossRef
A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha Cancer Research and Treatment.2005; 37(4): 208. CrossRef
Altered expression of KCNK9 in colorectal cancers CHANG JAE KIM, YONG GU CHO, SEONG WHAN JEONG, YOUNG SIL KIM, SU YOUNG KIM, SUK WOO NAM, SUG HYUNG LEE, NAM JIN YOO, JUNG YOUNG LEE, WON SANG PARK APMIS.2004; 112(9): 588. CrossRef
The E-cadherin −347G→GA promoter polymorphism and its effect on transcriptional regulation Yong Shin, Il-Jin Kim, Hio Chung Kang, Jae-Hyun Park, Hye-Rin Park, Hye-Won Park, Mi Ae Park, Jong Soo Lee, Kyong-Ah Yoon, Ja-Lok Ku, Jae-Gahb Park Carcinogenesis.2004; 25(6): 895. CrossRef
Reduced PTEN Expression Is Associated With Poor Outcome and Angiogenesis in Invasive Ductal Carcinoma of the Breast Ji Shin Lee, Hyung Seok Kim, Young Bog Kim, Min Cheol Lee, Chang Soo Park, Kyung Whan Min Applied Immunohistochemistry & Molecular Morphology.2004; 12(3): 205. CrossRef
Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays Hio Chung Kang, Il-Jin Kim, Jae-Hyun Park, Yong Shin, Ja-Lok Ku, Mi Sun Jung, Byong Chul Yoo, Hark Kyun Kim, Jae-Gahb Park Clinical Cancer Research.2004; 10(1): 272. CrossRef
Radiotherapy for Locally Advanced Lung Cancer Eun Kyung Choi Journal of the Korean Medical Association.2003; 46(1): 29. CrossRef
Yo Han Joh, Tae You Kim, Im Il Na, Do Youn Oh, Byung Su Kim, Jee Hyun Kim, Do Yeun Kim, Se Hoon Lee, Chul Gyu Yoo, Choon Taek Lee, Young Whan Kim, Dae Seog Heo, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim
Cancer Res Treat. 2001;33(5):373-376. Published online October 31, 2001
PURPOSE Platinum-based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in patients with advanced non-small cell lung cancer (NSCLC).
We performed a phase II trial in order to evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine (Navelbine) and cisplatin in advanced NSCLC. MATERIALS AND METHODS Patients with previously untreated, unresectable stage IIIB or IV NSCLC with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous vinorelbine 25 mg/m2, on day 1 and 8, and intravenous cisplatin 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS A total of 33 patients were enrolled in the study between July 1999 and Feb 2000. Of the 30 patients deemed eligible for analysis, thirteen patients achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis.
Chemotherapy-related grade 3 or 4 toxicities were anemia in 1.5%, leukopenia in 4.5%, nausea/vomiting in 2.3%, alopecia in 13.3%, and neurotoxicity in 3.3%. CONCLUSION The combination of vinorelbine and cisplatin chemotherapy seems to be active and fairly tolerable in patients with advanced NSCLC.
Citations
Citations to this article as recorded by
Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation Yibo Zhao, Yu Dong, Shu Xing, Xueqi Fu European Journal of Inflammation.2018; 16: 205873921878222. CrossRef
PURPOSE A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP). MATERIALS AND METHODS Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study.
One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks. RESULTS We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death. CONCLUSION This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC.
PURPOSE To investigate the effects of polyamines on tumor necrosis factor alpha (TNFalpha)-or tamoxifen (TAM)-induced apoptosis in estrogen receptor (ER)-positive MCF- 7 and ER-negative MDA-MB-231 human breast cancer cells. MATERIALS AND METHODS Cell viability was assessed by using MTT assay. Reactive oxygen species (ROS) generation was measured using 2', 7'-dichlorofluorescin diacetste (DCFDA) by fluorescence plate reader. DNA fragmentation was assessed by 1.5% agarose gel electrophoresis. RESULTS TNFalpah and TAM showed significant dose- and time- dependent inhibitory effects on the growth of MCF-7 human cells. However, the growth of MDA-MB-231 cells were not inhibited by TNFalpha or TAM treatment. The generation of ROS was increased in dose-and time-dependent manner by TNFalpha treatment in MCF-7 cells. Polyamines, especially spermine suppressed TNFalpha-induced ROS generation in MCF-7 cells. Antioxidant effects of polyamines were also demonstrated by DNA fragmentation, cell morphology as well as ROS generation assay. Polyamines also blocked TAM-induced cell death in MCF-7 cell. However, MDA-MB-231 cells showed resistance to the cytotoxic effects of TNFalpha or TAM. CONCLUSION These results suggest that polyamines may prevent TNFalpha or TAM-induced apoptosis in MCF-7 human breast cancer cells.
Citations
Citations to this article as recorded by
Influence of Estrogen and Polyamines on Mifepristone-induced Apoptosis in Prostate Cancer Cells Eun Kyung Choi, Hwi-June Song, Min S. Park, Byeong Gee Kim Cancer Research and Treatment.2004; 36(1): 85. CrossRef
PURPOSE Cancers are highly individual in their response to chemotherapy, however attempts to predict tumor response to drugs using in vitro cell culture have largely failed. A new technology, the histoculture drug response assay (HDRA), appears to have solved many previous problems. The purpose of this study is to evaluate the reliability of HDRA in a chemosensitivity test for breast cancer. MATERIALS AND METHODS Tumor specimens from breast cancer patients were evaluated by HDRA using different chemotherapeutic agents. Each specimen was tested using a blind method in order to determine the reproducibility of HDRA results for the same tissue and with a triplicated assay in order to determine reproducibility by different examiners. The evaluative power of this assay and the chemosensitivity of drugs for each specimen was determined. RESULTS Specimens of 92.9% (65/70) were successfully cultured and evaluated for chemosensitivity. The reproducibility of HDRA for the same tissue was 75% (100% agreement) and 100% (over 70% agreement), respectively. And the reproducibility by different examiners was 78.9% (100% agreement) and 94.7% (over 70% agreement), respectively.
Each specimen demonstrated a response to at least one agent. CONCLUSION The evaluative power and reproducibility of HDRA were high, therefore it might serve as a reliable clinical method for chemosensitivity testing. However, there is a need for clinical trial in which patients are initially randomized for treatment either by HDRA direction or by clinician's choice.
Citations
Citations to this article as recorded by
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response Yoshiyuki Tsukamoto, Yuka Hirashita, Tomotaka Shibata, Shoichi Fumoto, Shusaku Kurogi, Chisato Nakada, Keisuke Kinoshita, Takafumi Fuchino, Kazunari Murakami, Masafumi Inomata, Masatsugu Moriyama, Naoki Hijiya Cancers.2023; 15(16): 4104. CrossRef
Comparison of Forcep-biopsy and Cryo-biopsy by a Flexible Bronchoscopy Jae Hyun Kim, Jung Min Choi, Sung Eun Song, Eun Mi Lee, Song Ju Lee, Chul Ho Oak, Tae Won Jang, Man Hong Jung, Hee Kyung Jang Tuberculosis and Respiratory Diseases.2009; 66(2): 110. CrossRef
Can the Histoculture Drug Response Assay Predict the Clinical Results of Chemotherapy in Breast Cancer? Yong Sik Jung, Young Up Cho, Young Jin Suh, Jeong Soo Kim, Se-Jeong Oh, Cheol Wan Lim, Moon Bo Kim, Heung Kyu Park Journal of Breast Cancer.2007; 10(3): 193. CrossRef
A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer Shin Myung Kang, Moo Suk Park, Joon Chang, Se Kyu Kim, Haeryoung Kim, Dong-Hwan Shin, Kyung Young Chung, Dae Joon Kim, Joo Hyuk Sohn, Sung Ho Choi, Jeongmi Kim, Eun Jin Yoon, Joo-Hang Kim Cancer Research and Treatment.2005; 37(4): 223. CrossRef
Jeong Eun Lee, Dae Yong Kim, Yong Chan Ahn, Do Hoon Lim, Seung Jae Huh, Seong Soo Shin, Won Seok Kim, Won Ki Kang, Do Hyun Nam, Jung Il Lee, Jong Hyun Kim
Cancer Res Treat. 2001;33(5):398-403. Published online October 31, 2001
PURPOSE This study was performed in order to evaluate the effectiveness of combined chemotherapy and radiotherapy (RT) in primary central nervous system lymphoma (PCNSL). MATERIALS AND METHODS From January 1995 to August 1999, 21 patients with a diagnosis of PCNSL were treated with combined chemotherapy and radiotherapy. Their median age was 47 years with range of 19 to 78 years. Twelve patients were male and nine patients were female. All patients were immunocompetent and they had no evidence of systemic lymphoma. All patients underwent placement of an Ommaya reservoir and recieved a combination regimen using pre-RT systemic and intra-Ommaya methotrexate (MTX), 40 Gy whole-brain RT with a 14.4 Gy boost, and 2 courses of post-RT high-dose cytarabine. The median follow-up period of all patients and survived patients were 22 months and 36 months, respectively. RESULTS The median overall survival duration was 21 months and the overall two- and four-year survival rates were 51% and 43%, respectively. Complete response (CR), partial response, stable disease, and progressive disease were achieved in 12, 3, 1, and 5 patients, respectively. All nine patients without CR expired within 1-31 months (median 6 months). Two patients among the patients with CR developed recurrence after 13 and 14 months, respectively. The location of recurrent disease was within the port of radiation boost. Survival was influenced by age, performance status, and CR. There was one episode of MTX neurotoxicity and hepatotoxicity,respectively. CONCLUSION Combined chemotherapy and radiotherapy was an effective treatment for PCNSL, and was associated with a minimum toxicity. However, we must pay attention to the recurrence and late toxicity, particularly within two years following treatment.
PURPOSE Epidemiological and laboratory studies suggest that nonsteroidal antiinflammatory drugs (NSAIDs) reduce the risk of colon cancer and that the inhibition of colon cancer is mediated through modulation of eicosanoid production. The present study examined the effect of cyclooxygenase (COX) and lipoxygenase (LOX) inhibitors on colon cancer cell growth and prostaglandin E(2) (PGE(2)) or leukotriene B(4) (LTB(4)) secretion by these cells. MATERIALS AND METHODS The human colon adenocarcinoma cell lines, Caco-2 and HT-29 cells, were cultured in serum-free medium with various concentrations of indomethacin, piroxicam or esculetin in the presence of 0.15nM or 10nM linoleic acid. Cell number was estimated by MTT assay and PGE(2) and LTB(4) were analyzed by enzyme immunoassay. RESULTS The NSAIDs inhibited cell proliferation in a concentration-dependent manner. However, the potency and efficacy of each drug varied in the two cell lines. In Caco-2 cells, the effect of esculetin was higher than that of indomethacin, and piroxicam had no effect. In HT-29 cells, only indomethacin significantly inhibited cell proliferation. All three agents inhibited PGE(2) secretion in a dose-dependent manner; the effect of indomethacin was highest and that of esculetin lowest. The secretion of LTB4 was increased by indomethacin and piroxicam but decreased by esculetin. The effects of these drugs on cell proliferation and eicosanoid secretion were not influenced by linoleic acid concentrations in the culture media. Neither exogenous PGE2 nor LTB4 affected cell proliferation. The results of Pearson correlation analyses revealed that changes in cell proliferation were somewhat related to both concentrations of NSAIDs in the culture medium and production of PGE(2) and LTB(4). CONCLUSION The present data suggests that the anti-proliferative effect of NSAIDs may not be entirely attributed to changes in the production of PGE2 and/or LTB4 in the two colon cancer cell lines. These NSAIDs may inhibit cell proliferation largely independent of their ability to modulate eicosanoid synthesis.
Citations
Citations to this article as recorded by
Modulating effect of inositol hexaphosphate on arachidonic acid-dependent pathways in colon cancer cells Małgorzata Kapral, Joanna Wawszczyk, Stanisław Sośnicki, Katarzyna Jesse, Ludmiła Węglarz Prostaglandins & Other Lipid Mediators.2017; 131: 41. CrossRef
Soo Mee Bang, Eun Kyung Cho, Jae Hwan Oh, Heung Moon Chang, Jin Seok Ahn, Jung Ae Lee, Young Iee Park, Myung Jue Ahn, Young Suk Park, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2001;33(5):414-419. Published online October 31, 2001
PURPOSE To evaluate the efficacy and toxicity of oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer who previously treated with 5-FU-based chemotherapy. MATERIALS AND METHODS Between April 1999 and January 2001, thirty-two patients were enrolled in this study. Oxaliplatin 130 mg/m2 was given intravenously (IV) on day 1 as was 5-FU 500 mg/m2 IV followed by continuous infusion of 5-FU 3,000 mg/m2 and LV 100 mg/m2 for 48 hours administered every 3 weeks. Six patients had received 5-FU as an adjuvant setting and 26 patients as a palliative regimen. RESULTS The median age of the patients was 50 years (range; 19-69) and the dominant sites of metastasis were the liver, lung or both in 9, 5 and 2 patients respectively. In 30 evaluable patients, the overall response rate was 27% including 1 complete response and 7 partial responses. The median response duration was 28 weeks (95% confidence interval; 22~34 weeks) and the median progression free survival of all patients was 24 weeks (95% confidence interval; 15~33 weeks). A median 5 cycles (range; 2~9) and total 155 cycles were performed in 32 patients. 150 cycles were evaluable for toxicity. The most common hematologic toxicity was grade 1~2 anemia in 78 cycles (52%). Leukopenia (39%) and thrombocytopenia (23%) were fully reversible. The most common non-hematologic toxicity was nausea/vomiting (43/30%) followed by diarrhea (23%), hepatotoxicity (21%) and neurotoxicity (21%). One patient ceased therapy due to grade 4 diarrhea. No other severe toxicity interrupted this treatment. CONCLUSION Oxaliplatin, 5-FU and LV in combination showed significant activity in previously treated metastatic colorectal cancer with favorable toxicity.
Citations
Citations to this article as recorded by
Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim Cancer Research and Treatment.2005; 37(4): 212. CrossRef
PURPOSE The death rate of liver cancer in Korea has been reported as one of the highest in the world. This study was conducted to investigate geographical variations of liver cancer mortality in Korea in order to obtain insight into possible environmental factors related to liver cancer. MATERIALS AND METHODS The sex-specific standardized mortality ratios (SMRs) of liver cancer were calculated for 168 basic administrative units in Korea based upon the vital statistics for the seven years 1992 to 1998, as well as the sex- and age-specific population of each area for 1995. The SMRs were classified into six categories and depicted on a map for each sex. RESULTS The southern provinces showed clearly higher mortality rates as compared to the rest of the country in both males and females. Looking at the maps in detail, there was a geographical variation even within the southern provinces. The areas around large rivers, some costal areas, and costal islands showed a high mortality rate. Even in the middle and northern provinces, the eastern costal areas showed relatively higher mortality rates as compared to inland areas. Conversely, some southern areas known for low levels of pollution showed relatively lower mortality rates. CONCLUSION This finding suggests a possible relationship between liver cancer and water-related foods from polluted rivers or seas. Further studies should be performed in order to clarify which factors cause this geographical variation.
Citations
Citations to this article as recorded by
Prevalence and Related Factors of Clonorchiasis among Five Major Riverside Residents in South Korea Chunmi Kim, Kyung Ja June, Shin Hyeong Cho, Kyung Soon Park, Hung Sa Lee, Ji Yeon Park Journal of Korean Academy of Community Health Nursing.2016; 27(4): 346. CrossRef
The knowledge and attitudes towards hepatitis B among paramedic students Bo-Ram Choi, Dong-Ok Kim, Gyung-Hun Min The Korean Journal of Emergency Medical Services.2016; 20(3): 57. CrossRef
Viral Hepatitis and Liver Cancer in Korea: an Epidemiological Perspective Yohwan Yeo, Jin Gwack, Seokin Kang, Boyeon Koo, Sun Jae Jung, Prakash Dhamala, Kwang-Pil Ko, Young-Khi Lim, Keun-Young Yoo Asian Pacific Journal of Cancer Prevention.2013; 14(11): 6227. CrossRef
A Study on the Prevalence of Clonorchis Sinensis and the Effects of Educational Program among Residents in the Basin of the Youngsan River, Korea Chunmi Kim, Aeyoung So, Kyung-Ja June, Hee Young Jung Journal of Korean Academy of Community Health Nursing.2011; 22(1): 56. CrossRef
Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture H R Shin, J Y Kim, J I Kim, D H Lee, K Y Yoo, D S Lee, S Franceschi British Journal of Cancer.2002; 87(3): 314. CrossRef
PURPOSE It has been demonstrated that PLC-gamma1 is overexpressed in many tumor cells, and that overexpression of Phospholipase C (PLC)-gamma1 is associated with tumor progression. In order to understand the effect of the PLC-gamma1 overexpression on the regulation of cell cycle regulators following DNA damage, we analyzed the expression level of PCNA, cyclin B1, and p21 Waf1 after ultraviolet C (UVC) irradiation in PLC-gamma1-transfected PC12 cells. MATERIALS AND METHODS PC12 and 3Y1 cells, transfected with empty vector or rat PLC-gamma1 cDNA, were used for this study. Following UVC irradiation, cell cycle progression was analyzed by flow cytometry and protein expression was detected by Western blotting. RESULTS Waf1 protein was markedly down-regulated, whereas PCNA and cyclin B1 was up-regulated in PLC-gamma1 overexpressed-cells as compared to the vector transfected-cells. When the cells were irradiated with UVC, PCNA was slightly increased within 3-hours of the UV irradiation and then was markedly decreased in Vector/ PC12 cells, while it remained high until 37 hour after UVC in PLC-gamma1/PC12 cells. In contrast, cyclin B1 was gradually decreased following UVC irradiation in both cells. CONCLUSION The overexpression of PLC-gamma1 affects the expression level of PCNA after UVC irradiation. We proposed that the overexpression of PLC-gamma1 may contribute to the UV-induced genomic instability by up-regulating the expression of PCNA.
PURPOSE The dual-specificity phosphatase PTEN/ MMAC1/TEP1 has recently been identified as the tumor suppressor gene most frequently mutated and/or deleted in human tumors.
However, PTEN mutations have rarely been detected in sporadic thyroid cancers. Therefore, this study investigated the PTEN expression of thyroid cancer and the relationship between PTEN, clinical status and other biologic factors such as HER-2/neu and p53. MATERIALS AND METHODS The study samples consisted of 62 thyroid cancer specimens and 24 benign thyroid tumor specimens from patients who were operated on the Department of Surgery, Uijongbu St. Mary's hospital during the 5 years from January 1995 until January 2000. All tumors were studied by immunohistochemical staining using monoclonal antibodies against PTEN, HER-2/neu and p53. The results were analyzed statistically. RESULTS PTEN protein was found to be under-expressed more frequently in thyroid cancers (29%) than in benign thyroid tumors (4.2%). The reduction in PTEN expression in thyroid cancers was not significantly related with the recorded clinical factors such as size, age, lymph node metastasis and p53, except for HER-2 which was found to be significantly related (p=0.001). HER-2 over- expression was noted in thyroid cancer (83.8%) more frequently than in benign tumors (16.7%). CONCLUSION This study has demonstrated that the under-expression of PTEN protein and the over-expression of HER-2 protein may play a role in the carcinogenesis and development of thyroid cancer.
Citations
Citations to this article as recorded by
Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen Cancers.2022; 14(20): 5117. CrossRef
Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome L.A. Jonker, C.A. Lebbink, M.C.J. Jongmans, R.A.J. Nievelstein, J.H.M. Merks, E.J.M. Nieveen van Dijkum, T.P. Links, N. Hoogerbrugge, A.S.P. van Trotsenburg, H.M. van Santen European Thyroid Journal.2020; 9(5): 234. CrossRef
Activity of Green Tea Polyphenol Epigallocatechin-3-gallate Against Ovarian Carcinoma Cell Lines Yong Wook Kim, Su Mi Bae, Joon Mo Lee, Sung Eun Namkoong, Sei Jun Han, Byoung Rai Lee, Insu P. Lee, Sang Hee Kim, Young Joo Lee, Chong Kook Kim, Yong-Wan Kim, Woong Shick Ahn Cancer Research and Treatment.2004; 36(5): 315. CrossRef
Lymphomatous involvement of the heart is extremely rare at initial diagnosis and presentation of malignant lymphoma.
Worldwide, only a few cases have been diagnosed and treated during life and only four cases were diagnosed before death in Korea. We report a case of non-Hodgkin's lymphoma with two right atrial masses detected by chest computed tomography and transesophageal echocardiography. The patient was an 80 year- old man and the presenting symptoms included generalized weakness, weight loss, constipation and low abdominal pain. For diagnosis, the mass of the perinephric area was biopsied under ultrasonographic guidance, and pathologically it was determined to be malignant lymphoma, diffuse large B cell type. The patient was treated with continuous low dose cyclophosphamide and prednisolone vice standard chemotherapy because of advanced age and renal dysfunction. After 2 months of treatment the masses in the atrium and the intraabdominal masses disappeared.